The stock of CymaBay Therapeutics Inc. (NASDAQ:CBAY) decreased by -$0.54 on Tuesday to finish at $15.41, down -3.39 percent. The last five days have seen an average of 2,346,120 shares of common stock traded. 35 times new highs were reached in the current year, with a gain of $9.14. The average number of shares traded over the last 20 days was 3,333,485, while the average volume over the last 50 days totaled 2,143,610.
CBAY stock appreciated 29.71% since last month. On 08/21/23, the company’s shares reached a one-month low of $11.84. The stock touched a high of $18.20 on 09/12/23, after rallying from a low of $3.15 in 52 weeks. The price of CBAY stock has risen by 145.77% or $9.14 this year, reaching a new high 35 times. Still, the stock price is down -15.33% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
CBAY stock investors should be aware that CymaBay Therapeutics Inc. (CBAY) stock had its last reported insider trading activity 2 days ago on Sep 18. On Sep 18, President of R&D McWherter Charles sold 21,746 shares at $16.22 each. This transaction resulted in the insider making $352,733. On Sep 15, Quinlan Paul T sold 53,000 shares at a price of US$16.87. After the transaction, the insider now owns 0 shares. President of R&D McWherter Charles had earlier sold 21,746 shares on Aug 18 for $11.47 a share. The transaction was completed for $249,359.
Valuation Metrics
Beta for the stock is 0.33. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 56.19, the price-to-book (PB) ratio of 14.54.
Financial Health
For the three months ended June 29, CymaBay Therapeutics Inc.’s quick ratio was 12.50, while its current ratio was 12.50, indicating its ability to pay off its debt. The company’s long-term debt to equity ratio for the quarter ending June 29 is 0.92, and the total debt to equity ratio is 0.92. Based on annual data, it had gross profit of $14.91 million and revenue of $93.11 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. CBAY’s return on assets (ROA) during the last 12 months has been -41.80%. In the meantime, the return on equity (ROE) for the last 12 months was -104.50%.
Earnings Surprise
According to CymaBay Therapeutics Inc.’s quarterly financial report for the quarter that ended June 29. Net income for the quarter came in at $31.02 million, while revenues rose by 100.0% to $0.0. It was predicted that CymaBay Therapeutics Inc.’s quarterly earnings would be -$0.01, but it ended up being -$0.2, beating the consensus by 95.00%. EBITDA was -$1.88 million for the quarter. At the end of CymaBay Therapeutics Inc.’s most recent quarter ended June 29, its liabilities totaled 118.24 million, while its total debt was $99.62 million. Equity owned by shareholders amounts to $98.15 million.
Technical Picture
Here’s a quick look at CymaBay Therapeutics Inc.’s (CBAY) price momentum from a technical perspective. As of 19 September, the RSI 9-day stood at 51.17%, suggesting the stock is Neutral, with a 75.49% historical volatility rate.
The stochastic %K and %D were 55.20% and 64.47% respectively, while the average true range (ATR) was 1.00. Based on the 14-day stochastic reading of 44.20%, the RSI (14) reading is 55.94%. On the 9-day MACD Oscillator, the stock is at -0.44, and the 14-day reading is at 0.47.
Analyst Ratings
In its analyst report released on August 14, 2023, UBS began covering CymaBay Therapeutics Inc. (NASDAQ: CBAY). The stock was rated as a Buy by the brokerage firm. Analysts have assigned CymaBay Therapeutics Inc. (CBAY) an Buy rating. CBAY is a stock that is recommended for selling by 0 brokerage firms, while 0 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 13 others recommend it as a buy.
What is CBAY’s price target for the next 12 months?
The current consensus forecast for the stock is between $18.00 and $33.00, with a median target price of $21.50. In analyzing these forecasts, the average price target given by analysts for CymaBay Therapeutics Inc. (CBAY) is $22.17.
